Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.

International journal of cancer - 15 Mar 2019

Dizdar Levent, Werner Thomas A, Drusenheimer Jasmin C, Möhlendick Birte, Raba Katharina, Boeck Inga, Anlauf Martin, Schott Matthias, Göring Wolfgang, Esposito Irene, Stoecklein Nikolas H, Knoefel Wolfram T, Krieg Andreas

Abstract excerpt

To determine the role of BRAFV600E mutation and MAPK signaling as well as the effects of BRAF and MEK directed therapy in gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN), with a focus on highly aggressive gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). Using Sanger sequencing of BRAF exon 15 we determined the frequency of BRAFV600E mutations in 71 primary GEP-NENs. MEK phosphorylation was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to G1 Phase Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Intestinal Neoplasms

Share to Neuroendocrine Tumors

Share to Oximes

Share to Pyrimidinones

Share to Tissue Array Analysis

Share to Vemurafenib

Source

Identifiers

PMID: 30144031
DOI: 10.1002/ijc.31828

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.PMID 30144031Read ↗

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.Semantic proximity Read ↗

Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma.Semantic proximity Read ↗

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Semantic proximity Read ↗

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.Semantic proximity Read ↗

Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.Semantic proximity Read ↗

BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors.Semantic proximity Read ↗

Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.Semantic proximity Read ↗

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Semantic proximity Read ↗

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.Semantic proximity Read ↗

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.Semantic proximity Read ↗

Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.Semantic proximity Read ↗

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.